1. Challenges and Opportunities

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. Tumor Microenvironment

6. Rationale for Combination Therapies

7. PD-1 or PD-L1 Inhibition + Chemotherapy in NSCLC

8. Rationale for Combination Therapies

9. PD-1 or PD-L1 Inhibition + Targeted Therapies in RCC

10. PD-1 or PD-L1 Inhibition + Targeted Therapies in RCC (cont)

11. PD-1 Inhibition + Targeted Therapies in Melanoma

12. Ongoing Research into PD-1/PD-L1 Inhibition + Targeted Therapies

13. Effect of Baseline Steroid Use on PD-1/PD-L1 Outcomes

14. Co-Inhibitory Molecules: LAG-3

15. Results With LAG-3 Inhibition

16. Co-Inhibitory Molecules: TIM-3

17. TLR Agonists

18. TLR9 Agonists in Development

19. IL-2

20. IL-2 Molecules in Development

21. HDAC Inhibitors

22. A2a signaling

23. CD47

24. STING Agonists

25. ICOS

26. Immune-Related AEs

27. Overview of the Management of irAEs

28. Concluding Remarks

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)